Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.48 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.48 |
| ▸ | MAP4K3 | Q8IVH8 | 4/20 | 0.47 |
| ▸ | PAK1 | Q13153 | 3/20 | 0.46 |
| ▸ | ALK | Q9UM73 | 4/20 | 0.46 |
| ▸ | MET | P08581 | 2/20 | 0.45 |
| ▸ | GRK2 | P25098 | 1/20 | 0.44 |
| ▸ | GRK5 | P34947 | 1/20 | 0.44 |
| ▸ | PIM1 | P11309 | 1/20 | 0.44 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.44 |
| ▸ | PAK4 | O96013 | 2/20 | 0.43 |
| ▸ | INPPL1 | O15357 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3719529 | 0.90 | MAP4K3 (0.47) | IRAK4IRAK1MAP4K3PAK1ALK | |
| SCHEMBL3722850 | 0.89 | ALK (0.45) | IRAK4ALKMET | |
| SCHEMBL4174884 | 0.87 | IRAK4 (0.48) | IRAK4IRAK1MAP4K3PAK1ALK | |
| SCHEMBL3716555 | 0.87 | NTRK1 (0.57) | IRAK4IRAK1MAP4K3PAK1ALK | |
| SCHEMBL3718389 | 0.86 | MAP4K3 (0.53) | IRAK4IRAK1MAP4K3ALKMET | |
| SCHEMBL4174799 | 0.84 | IRAK4 (0.47) | IRAK4IRAK1MAP4K3PAK1ALK | |
| SCHEMBL3723926 | 0.84 | IRAK4 (0.47) | IRAK4IRAK1MAP4K3PAK1ALK | |
| SCHEMBL3717523 | 0.84 | MET (0.48) | MET | |
| SCHEMBL3728635 | 0.83 | ALK (0.43) | IRAK4ALKMETNTRK1 | |
| SCHEMBL3721843 | 0.82 | ACVR1B (0.44) | ALKPIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2242742-B1 | PYRIDINE DERIVATIVES | NOVARTIS AG (CH) | 2015-12-02 | — | — | EP | disclosed |
| US-8343966-B2 | Organic compounds | NOVARTIS AG (CH) | 2013-01-01 | — | — | US | disclosed |
| EP-2242742-A2 | ORGANIC COMPOUNDS | Novartis AG (CH) | 2010-10-27 | — | — | EP | disclosed |
| US-20090215776-A1 | Organic compounds | ADCOCK CLAIRE | 2009-08-27 | — | — | US | disclosed |
| WO-2009087212-A2 | PYRIDINE DERIVATIVES | NOVARTIS AG (CH) | 2009-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215776-A1 | Organic compounds | REN, RXFP1, MYLK | IRAK4 569/4885IRAK1 356/4885MAP4K3 3134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.